Gilead Sciences is buying blood cancer drug developer Arcellx for up to $7.8bn as pharmaceutical groups rush to acquire ...

By Jonathan Stempel NEW YORK, Feb 23 (Reuters) - Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral ...

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

Bayer sued Johnson and Johnson, alleging false advertising for its prostate cancer drug Erleada, claiming it misleads patients.

The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in women’s health.

Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste ...

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced ...

U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated ...

Feb 23 (Reuters) - Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug. Vir will receive $335 ...